RxDoctor Payments Data

Steven Omarro, MD

Infectious Disease · Springfield, ILNPI 1467552133

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.7% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Viiv Healthcare Company at 36.7% of the total. 2025 is the largest year on record at $582, 9.3 times the $63 reported in 2021.

$1,382in general payments, 2019–2025

Across 85 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$508
  • Insmed, Inc.$239
  • Shionogi Inc$149
  • EMD Serono, Inc.$141
  • Aimmune Therapeutics, Inc.$87
  • AbbVie$75
  • plus $183 from 5 others
$120,865in research payments, 2019–2025

Across 24 payments — averaging $5036.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astellas Pharma Global Development$75K
  • Insmed, Inc.$43K
  • Pfizer$2K

What the payments were for

  • Food & beverage$1,30995%
  • Education$745%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,382 in reported general payments places this provider in the 75th percentile of 368 infectious disease providers in Illinois.

See all infectious disease providers in Illinois

Medicare billing

Part B allowed, 2024
$138,819
Medicare patients
479
Services billed
1,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArikayceAmikacin Liposomal/Neb.Accessr17$255,676
OdefseyEmtricitab/Rilpiviri/Tenof Ala36$167,491
TriumeqAbacavir/Dolutegravir/Lamivudi26$124,574
GenvoyaElviteg/Cob/Emtri/Tenof Alafen24$101,926
Daptomycin56$95,009
DescovyEmtricitabine/Tenofov Alafenam34$87,987
PrezcobixDarunavir/Cobicistat34$86,389
BiktarvyBictegrav/Emtricit/Tenofov Ala19$73,526
IsentressRaltegravir Potassium35$70,143
TivicayDolutegravir Sodium25$56,551
VemlidyTenofovir Alafenamide25$44,802
EdurantRilpivirine Hcl16$25,360
Etravirine22$25,262
Vancomycin Hcl168$24,574
Cefepime Hcl71$22,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Descovy, Biktarvy, Vemlidy$29$308,241102 claims
Insmed, Inc.Arikayce$239$255,67617 claims
Viiv Healthcare CompanyTriumeq, Tivicay$508$181,12551 claims
MerckIsentress$14$70,14335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 368 infectious disease providers in Illinois.

Other infectious disease in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →